AI Article Synopsis

  • The study focuses on enhancing the safety of genetically modified live rabies vaccines by using a new mutation (G333Leu) that is less likely to revert to a pathogenic form compared to the previously used mutation (G333Glu).
  • While G333Glu demonstrated a risk of developing pathogenic characteristics after multiple passages in mice, G333Leu maintained its attenuated status without significant pathogenic reversion.
  • Both vaccine strains induced similar protective immune responses, but G333Leu proved to be a more stable and safer option for rabies vaccine development.

Article Abstract

To improve the safety of genetically modified live rabies vaccine strains, most studies have utilized an attenuating Arg-to-Glu mutation at position 333 in the glycoprotein (G333), which is responsible for attenuation of the live vaccine strain SAG2. The Glu residue requires two nucleotide substitutions to revert to pathogenic Arg, thus significantly lowering the probability of pathogenic reversion caused by the Glu-to-Arg mutation at G333. However, only one nucleotide substitution is sufficient to convert the Glu residue to another pathogenic residue, Lys, and thereby to cause pathogenic reversion. This indicates a potential safety problem of SAG2 and the live vaccine candidates attenuated by Glu at G333. In this study, aiming to solve this problem, we examined the utility of a Leu residue, which requires two nucleotide substitutions to be both Arg and Lys, as an attenuating mutation at G333. Using a reverse genetics system of the live vaccine strain ERA, we generated ERA-G333Leu by introducing an Arg-to-Leu mutation at G333. Similar to ERA-G333Glu, which is attenuated by an Arg-to-Glu mutation at G333, ERA-G333Leu did not cause obvious clinical signs in 6-week-old mice after intracerebral inoculation. Importantly, after 10 passages in suckling mouse brains, ERA-G333Glu acquired a pathogenic Lys or Arg at G333 and a high level of lethality in mice, whereas ERA-G333Leu retained the attenuating Leu at G333 and only showed a modest level of virulence probably caused by a mutation at G194. In addition, ERA-G333Leu and ERA-G333Glu induced neutralizing antibody response and protective immunity in mice with similar efficiencies. The results demonstrate that, compared to ERA-G333Glu, ERA-G333Leu is more stably attenuated, also indicating the high utility of a Leu residue as an attenuating mutation at G333 in the development of live rabies vaccine strains with a high level of safety.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2021.05.002DOI Listing

Publication Analysis

Top Keywords

mutation g333
20
live rabies
12
rabies vaccine
12
vaccine strain
12
leu residue
12
live vaccine
12
g333
9
genetically modified
8
modified live
8
attenuating leu
8

Similar Publications

Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.

Vaccine

July 2023

Joint Graduate School of Veterinary Sciences, Gifu University, Japan; Laboratory of Zoonotic Diseases, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan; Center for One Medicine Innovative Research (COMIT), Institute for Advanced Study, Gifu University, Japan. Electronic address:

Live rabies vaccines have advantageous features that can facilitate mass vaccination for dogs, the most important reservoirs/transmitters of rabies. However, some live vaccine strains have problems in their safety, namely, risks from the residual pathogenicity and the pathogenic reversion of live vaccine strains. The reverse genetics system of rabies virus provides a feasible option to improve the safety of a live vaccine strain by, for example, artificially introducing attenuating mutations into multiple viral proteins.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on enhancing the safety of genetically modified live rabies vaccines by using a new mutation (G333Leu) that is less likely to revert to a pathogenic form compared to the previously used mutation (G333Glu).
  • While G333Glu demonstrated a risk of developing pathogenic characteristics after multiple passages in mice, G333Leu maintained its attenuated status without significant pathogenic reversion.
  • Both vaccine strains induced similar protective immune responses, but G333Leu proved to be a more stable and safer option for rabies vaccine development.
View Article and Find Full Text PDF

Attenuated strains of rabies virus (RABV) have been used for oral vaccination of wild carnivores in Europe and North America. However, some RABV vaccines caused clinical rabies in target animals. To improve the safety of attenuated RABV as an oral vaccine for field use, strategies using selection of escape mutants under monoclonal antibody neutralization pressure and reverse genetics-defined mutations have been used.

View Article and Find Full Text PDF

Generation of a novel live rabies vaccine strain with a high level of safety by introducing attenuating mutations in the nucleoprotein and glycoprotein.

Vaccine

October 2017

Laboratory of Zoonotic Diseases, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan; The United Graduate School of Veterinary Sciences, Gifu University, Gifu, Japan.

The current live rabies vaccine SAG2 is attenuated by only one mutation (Arg-to-Glu) at position 333 in the glycoprotein (G333). This fact generates a potential risk of the emergence of a pathogenic revertant by a back mutation at this position during viral propagation in the body. To circumvent this risk, it is desirable to generate a live vaccine strain highly and stably attenuated by multiple mutations.

View Article and Find Full Text PDF

Characterization of the guanine-N7 methyltransferase activity of coronavirus nsp14 on nucleotide GTP.

Virus Res

September 2013

State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, PR China.

Most eukaryotic viruses that replicate in the cytoplasm, including coronaviruses, have evolved strategies to cap their RNAs. In our previous work, the nonstructural protein (nsp) 14 of severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as a cap (guanine-N7)-methyltransferase (N7-MTase). In this study, we found that GTP, dGTP as well as cap analogs GpppG, GpppA and m7GpppG could be methylated by SARS-CoV nsp14.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!